Case Report: Allogeneic adipose-derived mesenchymal stem cells for severe chronic kidney disease in a dog.
- 1College of Life Sciences, Yantai University, Yantai, Shandong, China.
- 2OUR PET Hospital, Shanghai, China.
Abstract
This case report explored the clinical improvement and short-term tolerability of allogeneic adipose-derived mesenchymal stem cells (AD-MSCs) in the treatment of severe chronic kidney disease (CKD) in dogs. A 9-year-old female Pomeranian was diagnosed with chronic kidney disease (CKD) caused by acute kidney injury and, after conventional treatment failed, received intravenous infusion of AD-MSCs from healthy donor dogs. The AD-MSCs were aseptically collected, isolated, cultured, characterized, and subjected to microbiological safety testing, and were then administered intravenously at a dose of 3 × 10⁶cells/kg every 2 weeks for a total of four infusions, with dexamethasone premedication to reduce the risk of adverse reactions. Following AD-MSC administration and continued conventional care, reductions in serum creatinine and phosphorus and a downward trend in blood urea nitrogen were observed, along with improvements in body weight, body condition score, appetite, and mental status; no adverse events were observed. The results of this case suggest the feasibility and short-term tolerability of allogeneic AD-MSCs for severe CKD in dogs and provide a reference for clinical research on cell-based therapy for canine CKD.
Related
- Intraglandular treatment with adipose-derived mesenchymal stem cells in patients with xerostomia due to Sjögren’s disease—a study protocol for aphase 1, triple-blinded, randomized, clinical trial
- Allogeneic Human Bone Marrow‐Derived Mesenchymal Stem Cells Accelerate Diabetic Wound Healing via Inflammation Suppression and Angiogenesis Promotion: A Preclinical Study
- Prednisolone attenuates the immunomodulatory capacity and reshapes the functional phenotype of canine adipose-derived mesenchymal stromal cells
- Exosome-mediated immunomodulatory and barrier-protective responses of adipose-derived mesenchymal stem cells in oleic acid-induced acute lung injury.
- Anti-Calcification Effects of Immortalized Human Adipose Tissue-Derived Mesenchymal Stem/Stromal Cell (HATMSC2) Secretome in an In Vitro Model of Vascular Calcification
BibTeX
@article{yu2026case,
title = {{Case Report: Allogeneic adipose-derived mesenchymal stem cells for severe chronic kidney disease in a dog.}},
author = {Yu Yu and Xuemin Lv and Xinyuan Zhou and Yuxin Ma and Hao Li and Weiwei Wang and Yizhe Song},
journal = {Frontiers in veterinary science},
year = {2026},
month = oct,
doi = {10.3389/fvets.2026.1977920},
url = {https://europepmc.org/article/MED/42909056},
note = {CC BY},
}
RIS
TY - JOUR
TI - Case Report: Allogeneic adipose-derived mesenchymal stem cells for severe chronic kidney disease in a dog.
AU - Yu Yu
AU - Xuemin Lv
AU - Xinyuan Zhou
AU - Yuxin Ma
AU - Hao Li
AU - Weiwei Wang
AU - Yizhe Song
PY - 2026
DA - 2026/10/07
JO - Frontiers in veterinary science
DO - 10.3389/fvets.2026.1977920
UR - https://europepmc.org/article/MED/42909056
AB - This case report explored the clinical improvement and short-term tolerability of allogeneic adipose-derived mesenchymal stem cells (AD-MSCs) in the treatment of severe chronic kidney disease (CKD) in dogs. A 9-year-old female Pomeranian was diagnosed with chronic kidney disease (CKD) caused by acute kidney injury and, after conventional treatment failed, received intravenous infusion of AD-MSCs from healthy donor dogs. The AD-MSCs were aseptically collected, isolated, cultured, characterized, and subjected to microbiological safety testing, and were then administered intravenously at a dose of 3 × 10⁶cells/kg every 2 weeks for a total of four infusions, with dexamethasone premedication to reduce the risk of adverse reactions. Following AD-MSC administration and continued conventional care, reductions in serum creatinine and phosphorus and a downward trend in blood urea nitrogen were observed, along with improvements in body weight, body condition score, appetite, and mental status; no adverse events were observed. The results of this case suggest the feasibility and short-term tolerability of allogeneic AD-MSCs for severe CKD in dogs and provide a reference for clinical research on cell-based therapy for canine CKD.
SN - 2297-1769
ER -